{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:45:09Z","timestamp":1792705509181,"version":"4.5.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction and objective<\/jats:title>\n                    <jats:p>Despite recent advances in the management of ST-segment elevation myocardial infarction (STEMI), the clinical outcome of some patients is still unsatisfactory. Therefore, early evaluation to identify high-risk individuals in STEMI patients is essential. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, as a new indicator that can reflect both nutritional status and inflammatory state of the body, can provide prognostic information. In this context, the present study was designed to investigate the relationship between HALP scores assessed at admission and no-reflow as well as long-term outcomes in patients with STEMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>A total of 1040 consecutive STEMI patients undergoing primary PCI were enrolled in this retrospective study. According to the best cutoff value of HALP score of 40.11, the study samples were divided into two groups. The long-term prognosis was followed up by telephone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Long-term mortality was significantly higher in patients with HALP scores lower than 40.11 than in those higher than 40.11. The optimal cutoff value of HALP score for predicting no-reflow was 41.38, the area under the curve (AUC) was 0.727. The best cutoff value of HALP score for predicting major adverse cardiovascular events (MACE) was 40.11, the AUC was 0.763. The incidence of MACE and all-cause mortality was higher in the HALP score &lt;40.11 group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HALP score can independently predict the development of no-reflow and long-term mortality in STEMI patients undergoing PCI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mca.0000000000001446","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T04:00:27Z","timestamp":1730692827000},"page":"273-280","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["The HALP score predicts no-reflow phenomenon and long-term prognosis in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention"],"prefix":"10.1097","volume":"36","author":[{"given":"Huiliang","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxiao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hebei General Hospital, Shijiazhuang, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"R1-20250506","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5334\/gh.1309","article-title":"Association of pre-PCI blood pressure and no-reflow in patients with acute ST-elevation coronary infarction.","volume":"19","author":"Li","year":"2024","journal-title":"Glob Heart"},{"key":"R2-20250506","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"R3-20250506","article-title":"Prognostic value of GRACE risk score combined with systemic immune-inflammation index in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention.","author":"Wang","year":"2023","journal-title":"Angiology"},{"key":"R4-20250506","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1161\/CIRCULATIONAHA.119.041297","article-title":"Resource and infrastructure-appropriate management of ST-segment elevation myocardial infarction in low- and middle-income countries.","volume":"141","author":"Chandrashekhar","year":"2020","journal-title":"Circulation"},{"key":"R5-20250506","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MCA.0000000000000726","article-title":"Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.","volume":"30","author":"Tasar","year":"2019","journal-title":"Coron Artery Dis"},{"key":"R6-20250506","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1093\/eurheartj\/ehx414","article-title":"Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials.","volume":"38","author":"de Waha","year":"2017","journal-title":"Eur Heart J"},{"key":"R7-20250506","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1067\/mhj.2003.36","article-title":"No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention.","volume":"145","author":"Resnic","year":"2003","journal-title":"Am Heart J"},{"key":"R8-20250506","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.3390\/jcm9092956","article-title":"No-reflow after PPCI\u2014a predictor of short-term outcomes in STEMI patients.","volume":"9","author":"Pantea-Ro\u0219an","year":"2020","journal-title":"J Clin Med"},{"key":"R9-20250506","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.3390\/jcm11082233","article-title":"\u2018No-reflow\u2019 phenomenon: a contemporary review.","volume":"11","author":"Annibali","year":"2022","journal-title":"J Clin Med"},{"key":"R10-20250506","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7150\/jca.27210","article-title":"The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is a novel significant prognostic factor for patients with metastatic prostate cancer undergoing cytoreductive radical prostatectomy.","volume":"10","author":"Guo","year":"2019","journal-title":"J Cancer"},{"key":"R11-20250506","doi-asserted-by":"crossref","first-page":"1206958","DOI":"10.3389\/fnut.2023.1206958","article-title":"Evaluating the baseline hemoglobin, albumin, lymphocyte, and platelet (HALP) score in the United States adult population and comorbidities: an analysis of the NHANES.","volume":"10","author":"Antar","year":"2023","journal-title":"Front Nutr"},{"key":"R12-20250506","doi-asserted-by":"crossref","first-page":"1173399","DOI":"10.3389\/fendo.2023.1173399","article-title":"Association of hemoglobin, albumin, lymphocyte, and platelet score with risk of cerebrovascular, cardiovascular, and all-cause mortality in the general population: results from the NHANES 1999\u20132018.","volume":"14","author":"Pan","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R13-20250506","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1536\/ihj.51.221","article-title":"Low serum albumin levels and in-hospital adverse outcomes in acute coronary syndrome.","volume":"51","author":"Hartopo","year":"2010","journal-title":"Int Heart J"},{"key":"R14-20250506","doi-asserted-by":"crossref","first-page":"4904217","DOI":"10.1155\/2020\/4904217","article-title":"Immune and inflammation in acute coronary syndrome: molecular mechanisms and therapeutic implications.","volume":"2020","author":"Wang","year":"2020","journal-title":"J Immunol Res"},{"key":"R15-20250506","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jacc.2009.11.051","article-title":"A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques.","volume":"55","author":"Reininger","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R16-20250506","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines.","volume":"127","author":"O\u2019Gara","year":"2013","journal-title":"Circulation"},{"key":"R17-20250506","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jacc.2009.03.054","article-title":"Myocardial no-reflow in humans.","volume":"54","author":"Niccoli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R18-20250506","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/00015385.2023.2299102","article-title":"The non-HDL-C\/HDL-C ratio is a strong and independent predictor of the no-reflow phenomenon in patients with ST-elevation myocardial infarction.","volume":"79","author":"Toprak","year":"2024","journal-title":"Acta Cardiol"},{"key":"R19-20250506","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.pharmthera.2011.05.010","article-title":"Management of the no-reflow phenomenon.","volume":"132","author":"Butler","year":"2011","journal-title":"Pharmacol Ther"},{"key":"R20-20250506","doi-asserted-by":"crossref","first-page":"S406","DOI":"10.1016\/j.ihj.2018.01.032","article-title":"The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: a meta-analysis.","volume":"70","author":"Fajar","year":"2018","journal-title":"Indian Heart J"},{"key":"R21-20250506","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2217\/fca-2020-0077","article-title":"No-reflow phenomenon in ST-segment elevation myocardial infarction: still the Achilles\u2019 heel of the interventionalist.","volume":"17","author":"Ciofani","year":"2021","journal-title":"Future Cardiol"},{"key":"R22-20250506","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1007\/s00380-019-01399-w","article-title":"Usefulness of fibrinogen-to-albumin ratio to predict no-reflow and short-term prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.","volume":"34","author":"Zhao","year":"2019","journal-title":"Heart Vessels"},{"key":"R23-20250506","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0041-1725979","article-title":"Pathophysiology, diagnosis, and management of coronary no-reflow phenomenon.","volume":"30","author":"Kaur","year":"2021","journal-title":"Int J Angiol"},{"key":"R24-20250506","doi-asserted-by":"crossref","first-page":"e13686","DOI":"10.1111\/eci.13686","article-title":"A score system to predict no-reflow in primary percutaneous coronary intervention: the PIANO score.","volume":"52","author":"Dai","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"R25-20250506","doi-asserted-by":"crossref","first-page":"131621","DOI":"10.1016\/j.ijcard.2023.131621","article-title":"A retrospective study: association of C-reactive protein and uric acid to albumin ratio with the no-reflow phenomenon in patients with ST elevation myocardial infarction.","volume":"397","author":"Yarlioglues","year":"2024","journal-title":"Int J Cardiol"},{"key":"R26-20250506","doi-asserted-by":"crossref","first-page":"e20230002","DOI":"10.36660\/abc.20230002","article-title":"Relationship between the fibrinogen\/albumin ratio and microvascular perfusion in patients undergoing primary percutaneous coronary intervention for ST-elevated myocardial infarction: a prospective study.","volume":"120","author":"Kaplangoray","year":"2023","journal-title":"Arq Bras Cardiol"},{"key":"R27-20250506","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/MCA.0000000000001285","article-title":"The prognostic importance of the Naples prognostic score for in-hospital mortality in patients with ST-segment elevation myocardial infarction.","volume":"35","author":"Saygi","year":"2024","journal-title":"Coron Artery Dis"},{"key":"R28-20250506","doi-asserted-by":"crossref","first-page":"e20230905","DOI":"10.1590\/1806-9282.20230905","article-title":"Could a reduced hemoglobin, albumin, lymphocyte, and platelet (HALP) score predict autoimmune hepatitis and degree of liver fibrosis?","volume":"70","author":"Ustaoglu","year":"2024","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"R29-20250506","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/MCA.0000000000001271","article-title":"The prognostic value of HALP score in predicting in-hospital mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.","volume":"34","author":"Karakayali","year":"2023","journal-title":"Coron Artery Dis"},{"key":"R30-20250506","doi-asserted-by":"crossref","first-page":"109496","DOI":"10.1016\/j.intimp.2022.109496","article-title":"Hemoglobin, albumin, lymphocyte, and platelet (HALP) score and cancer prognosis: a systematic review and meta-analysis of 13,110 patients.","volume":"114","author":"Xu","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"R31-20250506","doi-asserted-by":"crossref","first-page":"e16043","DOI":"10.7717\/peerj.16043","article-title":"Clinical value of hemoglobin, albumin, lymphocyte, and platelet indexes in predicting lymph node metastasis and recurrence of endometrial cancer: a retrospective study.","volume":"11","author":"Xiong","year":"2023","journal-title":"PeerJ"},{"key":"R32-20250506","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/ehf2.14662","article-title":"Association between haemoglobin, albumin, lymphocytes, and platelets and mortality in patients with heart failure.","volume":"11","author":"Liu","year":"2024","journal-title":"ESC Heart Fail"},{"key":"R33-20250506","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/00325481.2024.2319567","article-title":"The predictive value of the HALP score for no-reflow phenomenon and short-term mortality in patients with ST-elevation myocardial infarction.","volume":"136","author":"Toprak","year":"2024","journal-title":"Postgrad Med"},{"key":"R34-20250506","first-page":"106","article-title":"Relationship between hemoglobin concentration at admission with the incidence of no-reflow phenomenon and in-hospital mortality in acute myocardial infarction with elevation of ST segments in patients who underwent primary percutaneous coronary intervention.","volume":"32","author":"Akbar","year":"2022","journal-title":"Int J Angiol"},{"key":"R35-20250506","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10557-019-06901-0","article-title":"Pathophysiology, diagnosis, and management of the no-reflow phenomenon.","volume":"33","author":"Allencherril","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"R36-20250506","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.febslet.2008.04.057","article-title":"The antioxidant properties of serum albumin.","volume":"582","author":"Roche","year":"2008","journal-title":"FEBS Lett"},{"key":"R37-20250506","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.ijbiomac.2021.06.140","article-title":"Serum albumin levels and inflammation.","volume":"184","author":"Sheinenzon","year":"2021","journal-title":"Int J Biol Macromol"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T07:01:31Z","timestamp":1746514891000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001446","relation":{},"ISSN":["0954-6928","1473-5830"],"issn-type":[{"value":"0954-6928","type":"print"},{"value":"1473-5830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]}}}